Identification of Fecal Microbiota Biomarkers of Spondyloarthritis in Patients Suffering From Crohn's Disease.
Condition(s) studied
Investigational drug(s) / intervention(s)
Microbiota Sequencing: virome, bacteriome, fungome NGS sequencing
Study summary
The MICROSPA project aims to compare gut microbiota, serum cytokines, and PBMC of patients suffering from Crohn's disease (CD) associated or not to spondylarthritis (SpA). 3 groups of patients will be analyzed: patients suffering from CD alone, patients suffering from SpA alone, patients suffering from CD and SpA. One group of healthy controls will be analysed as a comparator. Fecal microbiota will be determined by bacteriome, virome and fungome NGS sequencing
Eligibility
Primary outcome measure(s)
- Alpha and Beta diversity of Fecal bacteriome — + 6 months
Alpha (number of species) and Beta diversity (distribution of species) - Alpha and Beta diversity of Fecal fungome — + 6 months
Alpha (number of species) and Beta diversity (distribution of species) - Alpha and Beta diversity of Fecal virome — + 6 months
Alpha (number of species) and Beta diversity (distribution of species)
Trial sites (2)
| Facility | City | Region | Status |
|---|---|---|---|
| Central Hospital | Nancy | Lorraine | Recruiting |
| Saint Antoine Hospital | Paris | France | Recruiting |
More Central Hospital, Nancy, France trials in France
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT03983473 on ClinicalTrials.gov ↗ ← All trials in France